Presentation is loading. Please wait.

Presentation is loading. Please wait.

Corifollitropin alfa doses based on body weight: clinical overview of drug exposure and ovarian response  William L. Ledger, Bart C.J.M. Fauser, Paul.

Similar presentations


Presentation on theme: "Corifollitropin alfa doses based on body weight: clinical overview of drug exposure and ovarian response  William L. Ledger, Bart C.J.M. Fauser, Paul."— Presentation transcript:

1 Corifollitropin alfa doses based on body weight: clinical overview of drug exposure and ovarian response  William L. Ledger, Bart C.J.M. Fauser, Paul Devroey, Anthe S. Zandvliet, Bernadette M.J.L. Mannaerts  Reproductive BioMedicine Online  Volume 23, Issue 2, Pages (August 2011) DOI: /j.rbmo Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions

2 Figure 1 Schematic representation of the therapeutic interventions in the corifollitropin alfa treatment regimen in relation to immunoreactivity measured by FSH immunoassay. GnRH=gonadotrophin-releasing hormone; HCG=human chorionic gonadotrophin; rFSH = recombinant FSH. Reproductive BioMedicine Online  , DOI: ( /j.rbmo ) Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions

3 Figure 2 Relationship between dose-normalized drug exposure to corifollitropin alfa (exposure to corifollitropin alfa normalized to the administered dose, dose normalized area under the curve (AUC)) and patient body weight. Reproductive BioMedicine Online  , DOI: ( /j.rbmo ) Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions

4 Figure 3 Relationship between mean number of oocytes per started cycle and dose of corifollitropin alfa: (A) 100μg for subjects ⩽60kg and (B) 150μg for subjects >60kg. Adapted from de Greef et al. (2010). Reproductive BioMedicine Online  , DOI: ( /j.rbmo ) Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions

5 Figure 4 Exposure to corifollitropin alfa (AUC) in Caucasian subjects. Horizontal white marks represent median values, boxes represent interquartile ranges and whiskers represent 5–95th percentiles. Pharmacokinetic parameters obtained by population pharmacokinetic analysis. Reproductive BioMedicine Online  , DOI: ( /j.rbmo ) Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions

6 Figure 5 Relationship between number of oocytes and potential predictors of ovarian response in Caucasian subjects after treatment with recommended dose of corifollitropin alfa: number of oocytes versus (A) AUC; (B) Cmax; (C) body weight; (D) basal FSH; (E) AFC; and (F) age. AFC = antral follicle count; AUC = area under curve; CI = confidence intervals; Cmax = peak serum concentration; P=percentile. Reproductive BioMedicine Online  , DOI: ( /j.rbmo ) Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions

7 Figure 6 Time profiles of the corifollitropin alfa serum concentration after administration of a recommended (green), too low (orange) or too high (red) dose of corifollitropin alfa. The arrows indicate the time point when follicular stimulation is no longer sustained by a single s.c. dose of corifollitropin alfa. PK=pharmacokinetic. Reproductive BioMedicine Online  , DOI: ( /j.rbmo ) Copyright © 2011 Reproductive Healthcare Ltd. Terms and Conditions


Download ppt "Corifollitropin alfa doses based on body weight: clinical overview of drug exposure and ovarian response  William L. Ledger, Bart C.J.M. Fauser, Paul."

Similar presentations


Ads by Google